MacroGenics Inc at Barclays Global Healthcare Conference Transcript
So, good morning. Welcome to Barclays Global Healthcare Conference in Miami and raise your hand or e-mail me if you have questions. My name is Peter Lawson. I'm one of the mid-cap biotech analysts at Barclays and really delighted to host (inaudible), President and CEO of MacroGenics.
Questions & Answers
So with that, I'm just -- I guess, love to start the questions on your B7-H3, and I guess, clinical trial for the Phase II, kind of how is that enrolling and when should we expect that to be enrolled?
Sure. Yes. First of all, Peter, thanks so much for the invitation today. And so many of you know, we've been pursuing multiple molecules towards B7-H3 with a lead molecule called vobramitamab duocarmazine, we sort of note this in short as vobra-duo. It was used to be called MGC018. This is an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
